PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: pricing
Obamacare After Nov 6th: Trouble for Pharma?
by Tom Norton
No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House. So close, in fact, it’s possible that no substantial political change will occur in Washington, as a result.
That said, for the U.S. pharmaceutical industry this is [...]
Also posted in Events, FDA, Legal, Market Access, R&D, Regulatory, leadership Tagged ACOs, CER, IPAB, Obamacare, PCORI 3 Comments
Ethics in Drug Innovation: The First Hurdle is Trust
By Ansis Helmanis
Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry. This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel [...]
Also posted in Europe, Events, FDA, Global, Guest Blog, Market Access, Patient Communication, Regulatory, healthcare, leadership Tagged CMS, Elie Wiesel, EMA, FDA, Guido Rasi, Margaret Hamburg, Prix Galien, reimbursement, sequestration Leave a comment
Video: Think Small, Be Stealthy
Also posted in Biotech, Global, Pharm Exec Magazine, R&D, Sales, Strategy Leave a comment
SciClone Pharmaceuticals: Selling Specialty Drugs in China
US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
Also posted in Biotech, Emerging Markets, Global, IP, Legal, Manufacturing, People, Regulatory, Sales, Strategy, compliance, healthcare Tagged China, Global, SciClone 1 Comment
IP Climate Change: Patent Rights Face Headwinds